ku-55933 and Inflammatory-Bowel-Diseases

Chronicles in Drug Discovery is a series of brief reports on timely topics in the field of drug R&D. This month's chronicles contain the following reports: Targeting DNA repair enzymes instead of viral proteins provides a great advantage in preventing the emergence of resistant mutants. A striking increase in therapeutic approaches for the treatment of IBD has been fueled by an improved understanding of the mechanisms that underlie its pathophysiology. Peptide deformylase inhibitors are under active investigation for bacterial infections and cancer treatment. Dopamine D3 receptors present an attractive target for alcoholism therapy since they are involved in the mechanisms of alcohol dependency and abuse.

Topics: Alcoholism; Amidohydrolases; Animals; Anti-Infective Agents; Antineoplastic Agents; Antiviral Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA-Binding Proteins; Dopamine Antagonists; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Inflammatory Bowel Diseases; Morpholines; Nitriles; Protein Serine-Threonine Kinases; Pyrones; Receptors, Dopamine D3; Tetrahydroisoquinolines; Tumor Suppressor Proteins